Lingeman James E, Preminger Glenn M, Berger Yithak, Denstedt John D, Goldstone Lawrence, Segura Joseph W, Auge Brian K, Watterson James D, Kuo Ramsay L
Clarian Health Partners, Methodist Hospital Institute for Kidney Stone Disease, Indiana University School of Medicine, Indianapolis, IN, USA.
J Urol. 2003 May;169(5):1682-8. doi: 10.1097/01.ju.0000055600.18515.a1.
An indwelling ureteral stent is commonly placed for 48 hours after uncomplicated ureteroscopy to maintain drainage and prevent postoperative complications. A propriety temporary ureteral drainage stent (TUDS, Boston Scientific/Microvasive, Natick, Massachusetts) was developed to satisfy this goal with the added advantages of biodegradability and spontaneous passage. We evaluated TUDS performance in a patient population.
A total of 88 patients at 6 centers were selected for TUDS placement. Device safety as well as effectiveness, defined as adequate intervention-free drainage for 48 hours with the maintenance of ureteral position, were the primary study end points. Secondary end points consisted of the time required to eliminate TUDS from the body, tolerability of device presence and passage, and overall patient satisfaction with the stent.
A single patient was excluded from primary end point analysis because of inadequate day 2 evaluation, resulting in an overall stent effectiveness rate of 78.2% (68 of 87 patients). Primary end point failure occurred in the remaining 19 patients (21.8%) with early stent extrusion in 17 and intervention required in 2 others within 48 hours of stent placement (cystoscopy and intravenous analgesia in 1, and intravenous analgesia alone in 1). There were no adverse clinical sequelae in 16 patients who experienced early extrusion with only 1 requiring intravenous pain medication. Stent fragments were retained beyond 3 months in 3 patients, of whom 2 were treated in a minimally invasive manner with shock wave lithotripsy, while 1 required ureteroscopy and shock wave lithotripsy to clear the residual fragments. Median time to stent elimination from the ureter and from the body was 8 and 15 days, respectively. Overall 71 of the 80 patients (89%) reported satisfaction with TUDS.
The concept of a self-degrading internal ureteral stent represents a new paradigm in ureteral drainage. TUDS combines adequate ureteral drainage and patient satisfaction after uncomplicated ureteroscopy, eliminating the need for stent removal.
在无并发症的输尿管镜检查后,通常留置输尿管支架48小时以维持引流并预防术后并发症。一种专有的临时性输尿管引流支架(TUDS,波士顿科学公司/微创公司,马萨诸塞州纳蒂克)被研发出来以实现这一目标,且具有生物可降解性和自然排出的额外优势。我们在一群患者中评估了TUDS的性能。
6个中心共88例患者被选择进行TUDS置入。设备安全性以及有效性(定义为在维持输尿管位置的情况下48小时内无干预的充分引流)是主要研究终点。次要终点包括从体内清除TUDS所需的时间、设备留置和排出的耐受性,以及患者对支架的总体满意度。
1例患者因第2天评估不充分被排除在主要终点分析之外,导致总体支架有效率为78.2%(87例患者中的68例)。其余19例患者(21.8%)出现主要终点失败,其中17例早期支架脱出,另外2例在支架置入后48小时内需要干预(1例进行膀胱镜检查和静脉镇痛,1例仅进行静脉镇痛)。16例经历早期脱出的患者无不良临床后遗症,仅1例需要静脉止痛药物。3例患者的支架碎片在3个月后仍有残留,其中2例采用微创方式进行冲击波碎石治疗,1例需要输尿管镜检查和冲击波碎石以清除残留碎片。输尿管和体内支架清除的中位时间分别为8天和15天。80例患者中有71例(89%)总体报告对TUDS满意。
自降解性输尿管内支架的概念代表了输尿管引流的一种新范例。TUDS在无并发症的输尿管镜检查后能实现充分的输尿管引流并使患者满意,无需取出支架。